Table 1.
Patient Characteristics
| Patient Population (N:22, 10F/12M) | Median (range) | ||
|---|---|---|---|
| Age, in years | 53 (35–66) | ||
|
| |||
| Time from diagnosis to ASCT, in months | 8 (4–14) | ||
|
| |||
| Time between cycles 1 and 2 of TASCT, in months | 63.5 (44-119) | ||
|
| |||
| Number of patients (: %) | |||
|
| |||
| Stage I II III | 2 (10) | 5 (22) | 15 (68) |
|
| |||
| M protein type: IgG IgA | 15 (68) | 7 (32) | |
|
| |||
| Del 13 by FISH | 9 (41) | ||
| Hyperploidy 5, 9, 15, 14, and /or 17 | 7 (32) | ||
| Hyperploidy 5, 9, or 15 and del 13 | 3 (14) | ||
| Normal | 7 (32) | ||
|
| |||
| Beta2 microglobulin at presentation > 3.5 | 2 (12) | ||
|
| |||
| Received thalidomide/dexamethasone | 8 (36) | ||
|
| |||
| Received bortezomib/dexamethasone | 9 (41) | ||
|
| |||
| Received lenolidomide/dexamethasone | 1 (5) | ||
|
| |||
| Received an anthracycline-containing regimen | 7 (32) | ||
|
| |||
| CR | VGPR | PR/SD | |
| Best response prior to TASCT | 2 (9) | 10 (45.5) | 10 (45.5) |
| Response after TASCT | 5 (23) | 11 (50) | 6 (27) |
| Best response after TASCT and maintenance | 12 (55) | 6 (27) | 4 (18) |
TASCT:tandem autologous stem cell transplant; CR: complete response; VGPR: very good partial response; PR: partial response; SD: stable disease